44IN - Tumor markers and biology in gastroesophageal cancer
|Date||01 October 2012|
|Event||ESMO Congress 2012|
|Session||From biology to treatment in advanced pancreatic and gastroesophageal cancer|
|Topics|| Oesophageal Cancer
|Presenter||Manfred P. Lutz|
Most patients with gastric cancer present with advanced disease. In these cases either multimodal therapy or palliative treatment is required. In most cases patients with locally advanced gastric cancer undergo neoadjuvant therapy and resection. In cases with distant metastasis palliative chemotherapy is given. While many patients show treatment response, in most patients cancers progress and change of treatment lines is required. Therefore, predicting treatment response in neoadjuvant and palliative chemotherapy is of special interest. While different molecular markers of treatment response have been described in various cancer, so far for esophageal and gastric cancer molecular response predictors are not well established. In some cases HER2/neu testing has shown additional value in combining chemotherapy with trastuzumab. However, molecular response predictors in Her2/neu positive cases are also lacking. Interestingly, recent data from breast cancers have shown that activation of src may mediate resistance to trastuzumab. Inasmuch as targeting of active src could be option to resensitize breast cancers to trastuzumab these studies need to be conducted in gastric cancers. Our own studies indicate that the inhibition of histone deacetylases may sensitize gastric cancers cells to epirubicine, which may also help to further individualize chemotherapy in gastric cancer.Disclosure
The author has declared no conflicts of interest.